Advertisements


Palmer: PRV-031 could be first ever disease modifying type 1 diabetes therapy

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

Researchers Discover a Breakthrough Drug That May Significantly Delay Type 1 Diabetes

A monoclonal antibody called teplizumab has been shown to delay the onset of type 1 diabetes for as long as two years. About 1.25 million Americans suffer from the disease, a form of diabetes in........»»

Category: blogSource: 247wallstJun 10th, 2019

Researcher one step closer to halting type 1 diabetes in kids

Researchers at Massachusetts General Hospital have been studying a generic drug that's shown potential to cure type 1 diabetes in adults. Now, researchers want to test the same drug in children with the disease. Dr. Denise Faustman, director of the Mas.....»»

Category: topSource: bizjournalsJun 6th, 2019

A new theory on why sleeping less than 7 hours per night can lead to heart disease and Type 2 diabetes

Decades of research has shown that chronic short sleep is associated with increased risk of clogged arteries, heart disease, and early mortality......»»

Category: topSource: marketwatchMay 18th, 2019

Why sleeping less than 7 hours can lead to heart disease and Type 2 diabetes

Decades of research has shown that chronic short sleep is associated with increased risk of clogged arteries, heart disease, and early mortality......»»

Category: topSource: marketwatchMay 3rd, 2019

23andMe eyes millions of more users with new report on diabetes

23andMe is adding a report to its health and ancestry DNA test for type 2 diabetes. That's a huge market opportunity as 1 in 3 people are at risk for developing the disease. More than 30 million people in the U.S. alone have diabetes......»»

Category: topSource: moneycentralMar 10th, 2019

6 simple, science-backed ways to get rid of belly fat

Shutterstock/ nd3000  Having lots of fat in the abdominal area is strongly linked to diseases like type 2 diabetes and heart disease. Excess sugar and carb consumptio.....»»

Category: topSource: businessinsiderApr 12th, 2018

Valeritas V-Go demonstrates benefits compared to MDI therapy for type 2 diabetes

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 2nd, 2018

Provention Bio May Offer New Hope For People With Type 1 Diabetes With Latest Clinical Data

Provention Bio May Offer New Hope For People With Type 1 Diabetes With Latest Clinical Data.....»»

Category: topSource: seekingalpha22 hr. 55 min. ago

FDA approves non-insulin Type 2 diabetes drug for kids, the first to hit market in 20 years

The U.S. Food and Drug Administration on Monday approved Novo Nordisk's Victoza, a liraglu.....»»

Category: topSource: marketwatchJun 17th, 2019

FDA approves Novo Nordisk"s Victoza for pediatric patients with type 2 diabetes

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 17th, 2019

Study: Whether You Eat Meat Before or After Veggies Can Dramatically Cut Type 2 Diabetes Risk

Switching to a diet based mostly on fruits and vegetables — but still including some lean meat and low-fat dairy — could reduce the risk of developing type 2 diabetes by as much as 60%,........»»

Category: blogSource: 247wallstJun 11th, 2019

Provention Bio announces results from At Risk study in Type 1 Diabetes

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 9th, 2019

Eli Lilly: FDA accepts NDA for triple combination tablet for type 2 diabetes

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 4th, 2019

Mitalipov responds to backlash against gene editing, following Chinese experiment

Shoukhrat Mitalipov, who directs the OHSU Center for Embryonic and Gene Therapy, is pushing back against calls for a moratorium on using gene-editing tools to prevent inherited disease. Miltalipov was among the many scientists condemning an experime.....»»

Category: topSource: bizjournalsJun 3rd, 2019

Bay Area researchers find new ways to attack diabetes

Technology has changed how scientists can approach treating the deadly disease......»»

Category: topSource: bizjournalsMay 23rd, 2019

An FDA Win For AstraZeneca Shifts To An Expanded Label In The Type 2 Diabetes Market

An FDA Win For AstraZeneca Shifts To An Expanded Label In The Type 2 Diabetes Market.....»»

Category: topSource: seekingalphaMay 21st, 2019

Atara Biotherapeutics: T-Cell Therapy Developer With Late-Stage Candidate In Rare Disease

Atara Biotherapeutics: T-Cell Therapy Developer With Late-Stage Candidate In Rare Disease.....»»

Category: topSource: seekingalphaMay 13th, 2019

The Wall Street Journal: Novartis therapy for infant muscle-wasting disease — potentially carrying a record $2 million price tag — is about to hit market

A new treatment for an infant muscle-wasting disease is about to go on sale at a potential cost of $2 million, a record price tag likely to fuel the continuing scrutiny of how companies price their drugs and how insurers pay for them......»»

Category: topSource: marketwatchMay 7th, 2019

AstraZeneca reports Qternmet XR approved in U.S. for type-2 diabetes

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 3rd, 2019

Potentially Good News for Those Who Suffer From Pompe Disease

There may be some good news developing for those who suffer from Pompe Disease. Amicus Therapeutics, Inc. (NASDAQ: FOLD) has reported pre-clinical data from its Pompe disease gene therapy program and........»»

Category: blogSource: 247wallstApr 30th, 2019